Extended N(6) substitution of rigid C2-arylethynyl nucleosides for exploring the role of extracellular loops in ligand recognition at the A3 adenosine receptor.

2-Arylethynyl-(N)-methanocarba adenosine 5'-methyluronamides containing rigid N(6)-(trans-2-phenylcyclopropyl) and 2-phenylethynyl groups were synthesized as agonists for probing structural features of the A3 adenosine receptor (AR). Radioligand binding confirmed A3AR selectivity and N(6)-1S,2R stereoselectivity for one diastereomeric pair. The environment of receptor-bound, conformationally constrained N(6) groups was explored by docking to an A3AR homology model, indicating specific hydrophobic interactions with the second extracellular loop able to modulate the affinity profile. 2-Pyridylethynyl derivative 18 was administered orally in mice to reduce chronic neuropathic pain in the chronic constriction injury model.

[1]  U. Schwabe,et al.  Characterization of adenosine receptors in rat brain by (−)[3H]N6-phenylisopropyladenosine , 1980, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  Kenneth A Jacobson,et al.  Exploring distal regions of the A3 adenosine receptor binding site: sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands. , 2004, Bioorganic & medicinal chemistry.

[3]  K. Jacobson,et al.  Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system. , 2008, Bioorganic & medicinal chemistry.

[4]  K. Jacobson,et al.  125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor. , 1994, Molecular pharmacology.

[5]  R. Freeman,et al.  MICROVASCULAR COMPLICATIONS-NEUROPATHY ( D ZIEGLER , SECTION EDITOR ) New and Developing Drugs for the Treatment of Neuropathic Pain in Diabetes , 2013 .

[6]  K. Jacobson,et al.  Pharmacological and therapeutic effects of A3 adenosine receptor agonists. , 2012, Drug discovery today.

[7]  K. Varani,et al.  Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications. , 2012, Journal of medicinal chemistry.

[8]  Kenneth A Jacobson,et al.  Recent developments in adenosine receptor ligands and their potential as novel drugs. , 2011, Biochimica et biophysica acta.

[9]  K. Jacobson,et al.  (N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. , 2005, Journal of medicinal chemistry.

[10]  Kenneth A Jacobson,et al.  Controlling murine and rat chronic pain through A3 adenosine receptor activation , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  S. McMahon,et al.  Understanding chronic inflammatory and neuropathic pain , 2012, Annals of the New York Academy of Sciences.

[12]  D. Chargelegue,et al.  Transgenic plants expressing antibodies: a model for phytoremediation , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  R. Stevens,et al.  Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.

[14]  A. Leslie,et al.  Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.

[15]  S. Moro,et al.  2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition. , 2009, Journal of medicinal chemistry.

[16]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[17]  Francesca Deflorian,et al.  Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. , 2012, Journal of medicinal chemistry.

[18]  K. Jacobson,et al.  Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position. , 2004, Bioorganic & medicinal chemistry.

[19]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[20]  M. Williams,et al.  [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. , 1989, The Journal of pharmacology and experimental therapeutics.

[21]  Manuel de Lera Ruiz,et al.  Adenosine A2A receptor as a drug discovery target. , 2014, Journal of medicinal chemistry.

[22]  Silvia Paoletta,et al.  Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. , 2013, Journal of medicinal chemistry.

[23]  Gary J. Bennett,et al.  A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man , 1988, Pain.

[24]  S. Oliver,et al.  Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects , 2010, Drug Metabolism and Disposition.